JZT(SZ:000989) Xin Lang Zheng Quan·2025-09-10 06:40Core Viewpoint - The stock price of Jiuzhitang has shown significant fluctuations in 2023, with a year-to-date increase of 38.85% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 10, Jiuzhitang's stock price rose by 2.21% to 10.64 CNY per share, with a trading volume of 1.22 billion CNY and a turnover rate of 1.67% [1] - The stock has experienced a 2.65% decline over the last five trading days and a 4.40% decline over the last twenty trading days, while it has increased by 19.69% over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Jiuzhitang reported a revenue of 1.265 billion CNY, a year-on-year decrease of 24.71%, and a net profit attributable to shareholders of 144 million CNY, down 29.71% year-on-year [3] - The company has distributed a total of 4.364 billion CNY in dividends since its A-share listing, with 935 million CNY distributed in the last three years [4] Group 3: Shareholder Information - As of June 30, 2025, Jiuzhitang had 50,500 shareholders, an increase of 25.14% from the previous period, with an average of 13,739 circulating shares per shareholder, a decrease of 20.09% [3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Steady Growth Mixed Fund, holding 1.996 million shares [4] Group 4: Business Overview - Jiuzhitang, established on May 12, 1999, and listed on June 28, 2000, is primarily engaged in the research, production, and sales of traditional Chinese medicine and biopharmaceuticals, with a revenue composition of 50.27% from prescription drugs and 46.11% from OTC products [2]